Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
What happenedIn its SEC filing dated May 14, 2026, Harvest Investment Services, LLC reported selling its entire stake of 356,114 shares in Adaptive Biotechnologies (ADPT +1.72%) during the first quarter. The estimated value of the shares sold was ~$5.67 million, based on the mean unadjusted closing price for the quarter. The quarter-end value of the position dropped by $5.78 million, a figure that accounts for both trading and price movement.What else to knowThis was a complete exit; Adaptive Biotechnologies now represents 0% of Harvest's 13F reportable assetsTop five holdings after the filing
:NASDAQ: LMBS: $44.61 million (8.16% of AUM)NYSEMKT: GLD: $17.79 million (3.25% of AUM)NYSEMKT: SLV: $13.42 million (2.45% of AUM)NASDAQ: SSRM: $10.49 million (1.92% of AUM)NASDAQ: PLTR: $8.93 million (1.63% of AUM)As of May 26, 2026, Adaptive Biotechnologies shares were priced at $114.09, up 57.78% over the prior year, outperforming the S&P 500 by 28.3 percentage pointsCompany overviewMetricValuePrice (as of May 26, 2026)$14.09Market capitalization$2.25 billionRevenue (TTM)$295.41 millionNet income (TTM)($49.64 million)Company snapshotOffers immunosequencing platforms (immunoSEQ), clinical di
agnostics (clonoSEQ, T-Detect), and research tools for immune system profiling, with revenue primarily generated from product sales and service contracts.Operates a commercial-stage business model focused on recurring revenue from diagnostic testing, research collaborations, and strategic partnerships in the biotechnology sector.Serves life sciences researchers, clinical laboratories, pharmaceutical companies, and healthcare providers targeting oncology, autoimmune, and infectious disease markets.Adaptive Biotechnologies leverages proprietary immune medicine technology to enable advanced diagnostics and monitoring of immune-driven diseases.
The company’s strategy centers on expanding its platform applications and forging key partnerships with industry leaders such as Genentech and Microsoft. A differentiated focus on immunosequencing and minimal residual disease detection positions Adaptive as a competitive player in the biotechnology and diagnostics landscape.What this transaction means for investorsHarvest Investment Services has grown the size of its portfolio from less than $100 million at the end of 2022 to more than $500 million at the end of this March. While the portfolio’s performance makes Harvest look like a good money manager to follow, it’s probably not a great idea to read too much into its recent sale of Adaptive Biotechnologies stock.
The diagnostics company was one of 48 positions that the firm closed out completely during the first quarter.Harvest could end up regretting its recent sale of Adaptive Biotechnologies stock. First-quarter sales of the company’s cancer tests that confirm minimal residual disease (MRD) status shot up by 53% year over year. Providing MRD testing services to drug developers is a small part of Adaptive Biotechnologies business right now, but it could become a significant growth driver down the road. In the first quarter, the company received its first U.S. big milestone payment for helping a clini
cal trial reach its primary endpoint.